Are medication restrictions before FOBT necessary? Practical advice based on a systematic review of the literature;Faut-il restreindre la médication avant une RSOS? Conseils pratiques fondés sur une synthèse critique de la littérature médicale

Canadian Family Physician

Volumn 58, Issue 9, 2012, Pages

  Konrad, Gerald ^a   Katz, Alan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ASCORBIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICOUMAROL; FENOPROFEN; FERROUS CALCIUM CITRATE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; GUAIAC; HEPARIN; IBUPROFEN; IRON; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

CANCER SCREENING; COLORECTAL CANCER; DRUG EFFECT; DRUG MEGADOSE; DRUG SYNTHESIS; EVENING DOSAGE; FECES ANALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; OCCULT BLOOD; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASCORBIC ACID; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; GUAIAC; HEMATOLOGIC AGENTS; HUMANS; INDICATORS AND REAGENTS; IRON; OCCULT BLOOD; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; TRACE ELEMENTS; VITAMINS; WITHHOLDING TREATMENT;

EID: 84867366695     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Rockville, MD: US Preventive Services Task Force; 2008. Accessible à: www.uspreventiveser- vicestaskforce.org/uspstf/uspscolo.htm. Accédé le 1er août 2011.
2. Société canadienne du cancer. Population-based colorectal cancer screening. Toronto, ON: Société canadienne du cancer; 2008. Accessible à: www.cancer.ca/Canada-wide/Prevention/Getting%20checked/ Colorectal%20cancer%20screening.aspx?sc-lang=en. Accédé le 1er août 2012.
3. Friedman LC, Webb JA, Richards CS, Plon SE. Psychological and behavioral factors associated with colorectal cancer screening among Ashkenazim. Prev Med 1999;29(2):119-25. (Pubitemid 29406787)
4. Zapka JG, Puleo E, Vickers-Lahti M, Luckmann R. Healthcare system factors and colorectal cancer screening. Am J Prev Med 2002;23(1):28-35. (Pubitemid 34687129)
5. Weitzman ER, Zapka J, Estabrook B, Goins KV. Risk and reluctance: understanding impediments to colorectal cancer screening. Prev Med 2001;32(6):502-13. (Pubitemid 32568520)
6. Manne S, Markowitz A, Winawer S, Meropol NJ, Haller D, Rakowski W et collab. Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol 2002;21(1):3-15. (Pubitemid 34158007)
7. Brawarsky P, Brooks DR, Mucci LA. Correlates of colorectal cancer testing in Massachusetts men and women. Prev Med 2003;36(6):659-68. (Pubitemid 36555545)
8. Brawarsky P, Brooks DR, Mucci LA, Wood PA. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev 2004;28(4):260-8. (Pubitemid 40125376)
9. Brenes GA, Paskett ED. Predictors of stage of adoption for colorectal cancer screening. Prev Med 2000;31(4):410-6.
10. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89(19):1406-22. (Pubitemid 27419204)
11. Hoogewerf PE, Hislop TG, Morrison BJ, Burns SD, Sizto R. Health belief and compliance with screening for fecal occult blood. Soc Sci Med 1990;30(6):721-6. (Pubitemid 20099743)
12. O'Malley AS, Beaton E, Yabroff KR, Abramson R, Mandelblatt J. Patient and provider barriers to colorectal cancer screening in the primary care safety-net. Prev Med 2004;39(1):56-63. (Pubitemid 38797956)
13. Sangster JF, Gerace TM, Bass MJ. Hemoccult II screening for bowel cancer: will family practice patients accept it? Can Fam Physician 1986;32:289-95.
14. Dent OF, Bartrop R, Goulston KJ, Chapuis PH. Participation in faecal occult blood screening for colorectal cancer. Soc Sci Med 1983;17(1):17-23. (Pubitemid 13142951)
15. Sewitch MJ, Fournier C, Ciampi A, Dyachenko A. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol 2007;7:39.
16. Konrad G. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can Fam Physician 2010;56:229-38.
17. Rabeneck L, Zwaal C, Goodman JH, Mai V, Zamkanei M. Cancer care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: evidentiary base and recommendations. Clin Biochem 2008;41(16-17):1289-305.
18. Barada K, Abdul-Baki H, El H 2nd, Hashash JG, Green PH. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. J Clin Gastroenterol 2009;43(1):5-12.
19. Beckman Coulter. Hemoccult II® patient instructions. Fullerton, CA: Beckman Coulter; 2005. Accessible à: http://hemoccultfobt.com/patients/ patients-HemoII-Pt-Instr.htm. Accédé le le1er août 2011.
20. Beckman Coulter. Hemoccult II® SENSA® patient instructions. Fullerton, CA: Beckman Coulter; 2005. Accessible à: http://hemoccultfobt. com/patients/patients-HemoII-Sensa-Pt-Instr.htm. Accédé le1er août 2011.
21. Cenogenics. TRI-SLIDE insert. Morganville, NJ: Cenogenics; 2008. Accessible à: www.cenogenics.net/pdf/tri-slide-insert.pdf. Accédé le 1er août 2011.
22. BC Biomedical Laboratories. A test for fecal occult blood. Surrey, BC: BC Biomedical Laboratories; 2007. Accessible à: www.bcbio.com/pdfs/ INS007ColoscreenEnglish.pdf. Accédé le1er août 2011.
23. LifeLabs Medical Laboratory Services. Instructions for Hema-Screen II test card. Toronto, ON: LifeLabs; 2009. Accessible à: www.lifelabs.com/files/BC/patients/Stool-Occult-Blood-Hema-screen-Card.pdf. le1er août 2011.
24. Sharma VK, Vasudeva R, Howden CW. Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol 2000;95(6):1551-6. (Pubitemid 30396319)
25. Sharma VK, Corder FA, Fancher J, Howden CW. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test. Am J Gastroenterol 2000;95(12):3629-32.
26. Sharma VK, Corder FA, Raufman JP, Sharma P, Fennerty MB, Howden CW. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance. Am J Gastroenterol 2000;95(8):2068-73.
27. Fries JF, Britton MC. Fenoprofen calcium in rheumatoid arthritis. A controlled double-blind crossover evaluation. Arthritis Rheum 1973;16(5):629-34.
28. Greenberg PD, Cello JP, Rockey DC. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999;50(5):618-22. (Pubitemid 29518041)
29. Brooks CD, Schmid FR, Biundo J, Blau S, Gonzalez-Alcover R, Gowans JD et collab. Ibuprofen and aspirin in the treatment of rheumatoid arthritis. A cooperative double-blind trial. Rheumatol Phys Med 1970;10(Suppl 10):10-63.
30. Zuin M, Podda M, Selmi C, Giorgini A, Zermiani P, Mandelli G et collab. Gastrointestinal tolerability of ibuprofen administered in two pharmaceutical formulations. Arzneimittelforschung 2000;50(9):837-42.
31. Hurlen M, Eikvar L, Seljeflot I, Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. Thromb Res 2006;118(4):433-8. (Pubitemid 44292794)
32. Bahrt KM, Korman LY, Nashel DJ. Significance of a positive test for occult blood in stools of patients taking anti-inflammatory drugs. Arch Intern Med 1984;144(11):2165-6. (Pubitemid 15215505)
33. Norfleet RG. 1,300 mg of aspirin daily does not cause positive fecal Hemoccult tests. J Clin Gastroenterol 1983;5(2):123-5. (Pubitemid 13110385)
34. Greenberg PD, Cello JP, Rockey DC. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med 1996;100(6):598-604. (Pubitemid 26243668)
35. Niv Y. Influence of non-steroidal anti-inflammatory drugs in faecal occult blood tests. Br Med J (Clin Res Ed) 1987;295(6595):446. (Pubitemid 17120989)
36. Pye G, Ballantyne KC, Armitage NC, Hardcastle JD. Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer. Br Med J (Clin Res Ed) 1987;294(6586):1510-1. (Pubitemid 17108386)
37. Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med 2004;117(11):837-41. (Pubitemid 39602792)
38. Clarke P, Jack F, Carey FA, Steele RJ. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 2006;8(5):389-92. (Pubitemid 43676653)
39. Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010;55(6):1637-42.
40. Doran J, Hardcastle JD. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg 1982;69(12):711-3. (Pubitemid 13201860)
41. Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the Hemoccult as a screening test in patients taking anticoagulants. Cancer 1984;54(12):3054-8. (Pubitemid 15184093)
42. Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987;83(2):269-72.
43. Kershenbaum A, Lavi I, Rennert G, Almog R. Fecal occult blood test performance indicators in warfarin-treated patients. Dis Colon Rectum 2010;53(2):224-9.
44. Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 2005;100(7):1586-92. (Pubitemid 41032368)
45. Iles-Shih L, Collins JF, Holub JL, Lieberman DA. Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin. Am J Gastroenterol 2010;105(9):2030-5.
46. Lifton LJ, Kreiser J. False-positive stool occult blood tests caused by iron preparations. A controlled study and review of literature. Gastroenterology 1982;83(4):860-3. (Pubitemid 12060525)
47. Kulbaski MJ, Goold SD, Tecce MA, Friedenheim RE, Palarski JD, Brancati FL. Oral iron and the Hemoccult test: a controversy on the teaching wards. N Engl J Med 1989;320(22):1500. (Pubitemid 19143728)
48. McDonnell WM, Ryan JA, Seeger DM, Elta GH. Effect of iron on the guaiac reaction. Gastroenterology 1989;96(1):74-8. (Pubitemid 19046269)
49. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985;312(22):1422-8. (Pubitemid 15083660)
50. Morris DW, Hansell JR, Ostrow JD, Lee CS. Reliability of chemical tests for fecal occult blood in hospitalized patients. Am J Dig Dis 1976;21(10):845-52.
51. Laine LA, Bentley E, Chandrasoma P. Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation. Dig Dis Sci 1988;33(2):172-7. (Pubitemid 18054679)
52. Eliakim R, Fich A, Mor-Yosef S, Granot E. Effect of different iron preparations on various tests for occult blood in feces. Isr J Med Sci 1988;24(6):328-9.
53. Coles EF, Starnes EC. Use of HemoQuant assays to assess the effect of oral iron preparations on stool Hemoccult tests. Am J Gastroenterol 1991;86(10):1442-4.
54. Anderson GD, Yuellig TR, Krone RE Jr. An investigation into the effects of oral iron supplementation on in vivo Hemoccult stool testing. Am J Gastroenterol 1990;85(5):558-61. (Pubitemid 20164313)
55. Jaffe RM, Kasten B, Young DS, MacLowry JD. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975;83(6):824-6.
56. Jaffe RM, Zierdt W. A new occult blood test not subject to false-negative results from reducing substances. J Lab Clin Med 1979;93(5):879-86. (Pubitemid 10160715)
57. Zierdt WS, Zierdt CH. Occult blood testing using tetramethylbenzidine in an extraction procedure for patients on unrestricted diets. Am J Clin Pathol 1985;83(4):486-8. (Pubitemid 15083914)
58. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ et collab. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343(22):1603-7. (Pubitemid 32162983)
59. Tunget CL, Clark RF, Manoguerra AS, Turchen SG. Iron overdose and detection of gastrointestinal bleeding with the Hemoccult and Gastroccult assays. Ann Emerg Med 1995;26(1):54-7.
60. Barrett JF. Effect of ascorbic acid on the chemical tests for blood. Lancet 1936;228(5908):1214.
61. Garrick DP, Close JR, McMurray W. Detection of occult blood in faeces. Lancet 1977;2(8042):820-1.
62. Gogel HK, Tandberg D, Strickland RG. Substances that interfere with guaiac card tests: implications for gastric aspirate testing. Am J Emerg Med 1989;7(5):474-80. (Pubitemid 19235802)
63. Imperiale TF. Continue or discontinue warfarin for fecal occult blood testing in 2010? Does the published evidence provide an answer? Am J Gastroenterol 2010;105(9):2036-9.
64. Rose IS, Young GP, St John DJ, Deacon MC, Blake D, Henderson RW. Effect of ingestion of hemoproteins on fecal excretion of hemes and porphyrins. Clin Chem 1989;35(12):2290-6. (Pubitemid 20017683)
65. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E et collab. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009;104(4):933-8.
66. Chieffi M, Kirk JE. The ascorbic acid excretion in the stool in elderly subjects. J Nutr 1956;59(2):273-6.